Saturday 17 October 2026
Export HALO’s income statement to Excel — free account
Halozyme Therapeutics, Inc.
HALO Healthcare Biotechnology
Halozyme Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.4 billion, up 37.6% from fiscal 2024. In the quarter to June 2026, revenue grew 47.7%, EPS grew 44.1%, free cash flow grew 141.2% and total debt rose 42.2%, each against the same quarter a year earlier. Revenue growth for five consecutive years, operating cash flow growth for three.
121.84
0.33
+0.27%
Follow HALO
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | Dec '16 | |
|---|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
25.79 | 13.66 | 17.47 | 37.25 | 14.11 | 44.49 | 0.00 | 0.00 | 50.50 | 0.00 |
Piotroski F-Score |
5 | 9 | 8 | 4 | 5 | 7 | 3 | 3 | 7 | 2 |
P/S ratio |
5.77 | 5.97 | 5.95 | 11.43 | 12.76 | 21.74 | 13.06 | 13.83 | 8.70 | 8.71 |
Altman Z-Score |
3.46 | 4.31 | 3.41 | 4.14 | 5.77 | 8.55 | 2.67 | 5.48 | 5.91 | (0.12) |
P/FCF ratio |
12.51 | 12.95 | 13.21 | 28.87 | 18.98 | 107.68 | 0.00 | 0.00 | 20.77 | 0.00 |
Altman Z″-Score (non-manufacturers) |
3.02 | 5.60 | 3.93 | 3.50 | 6.54 | 0.88 | 1.23 | 0.52 | 3.26 | (4.49) |
Beneish M-Score |
(2.59) | (2.33) | (2.74) | (0.57) | 0.26 | (1.25) | (1.56) | (1.35) | (0.87) | (4.61) |
P/Operating CF |
36.82 | 33.98 | 48.19 | 91.50 | 68.54 | 114.25 | (96.11) | 200.81 | 17.98 | (81.08) |
P/B ratio |
165.22 | 16.67 | 58.86 | 44.43 | 28.71 | 38.51 | 27.89 | 8.44 | 13.23 | 0.00 |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | 28.71 | 38.51 | 27.89 | 8.44 | 13.23 | 0.00 |
EV/Sales |
7.72 | 6.90 | 7.39 | 13.16 | 13.06 | 23.32 | 12.96 | 12.33 | 7.86 | 8.79 |
EV/EBITDA |
19.20 | 11.13 | 14.47 | 26.64 | 20.33 | 38.40 | 0.00 | 0.00 | 29.41 | 0.00 |
EV/Operating CF |
16.54 | 14.62 | 15.77 | 36.18 | 19.34 | 112.53 | (29.74) | (37.83) | 18.57 | (25.60) |
EV/FCF |
16.72 | 14.96 | 16.42 | 33.25 | 19.43 | 115.50 | (28.39) | (34.58) | 18.75 | (24.10) |
Quick Ratio |
3.30 | 6.50 | 5.07 | 4.54 | 7.10 | 1.11 | 5.61 | 2.57 | 3.74 | 4.04 |
Current Ratio |
4.66 | 7.80 | 6.64 | 5.65 | 7.91 | 1.32 | 6.35 | 2.86 | 3.89 | 4.70 |
Net Debt/EBITDA |
3.56 | 1.45 | 2.75 | 3.51 | 0.48 | 0.18 | 0.29 | 3.33 | (3.15) | (0.17) |
Debt/Assets |
84.85% | 72.97% | 86.50% | 81.79% | 79.38% | 68.50% | 71.14% | 28.71% | 38.92% | 82.83% |
Debt/Equity |
43.89 | 4.14 | 17.89 | 8.87 | 4.45 | 2.63 | 4.39 | 0.51 | 0.97 | (6.67) |
Asset Turnover |
0.61 | 0.53 | 0.46 | 0.45 | 0.53 | 0.47 | 0.39 | 0.32 | 0.81 | 0.66 |
Operating CF/Net income |
2.06 | 1.08 | 1.38 | 1.19 | 0.74 | 0.43 | 1.18 | 0.62 | 2.13 | 0.49 |
Capex/Depreciation |
(0.08) | (0.14) | (0.18) | 0.36 | (0.16) | (0.08) | (0.99) | (5.53) | (0.37) | (0.20) |
Interest Coverage |
25.87 | 30.48 | 17.99 | 15.79 | 36.66 | 7.08 | (5.81) | (3.84) | 3.68 | (4.17) |
| 153.59% | 198.42% | 222.07% | 110.23% | 231.44% | 106.33% | (42.41%) | (35.14%) | 71.60% | (1,958.98%) | |
| 13.81% | 23.39% | 15.75% | 13.72% | 47.82% | 22.53% | (14.36%) | (16.73%) | 16.12% | (46.48%) | |
ROIC |
14.31% | 27.06% | 16.92% | 12.73% | 51.83% | 50.02% | (57.81%) | (208.92%) | 0.00% | 0.00% |
Return on Tangible Assets |
43.39% | 43.48% | 39.72% | 29.56% | 49.24% | 89.66% | (15.41%) | (28.09%) | 16.46% | (49.96%) |
Average Days of Receivables |
115.33 | 110.89 | 103.09 | 127.77 | 74.90 | 133.30 | 110.70 | 72.12 | 25.52 | 39.02 |
Research and Development Expense of Revenue |
26.23% | 7.79% | 9.21% | 10.09% | 8.05% | 12.79% | 71.84% | 98.94% | 47.58% | 102.83% |
Selling, General and Administrative Expense of Revenue |
14.83% | 15.20% | 17.99% | 21.74% | 11.35% | 17.09% | 39.42% | 40.04% | 17.00% | 31.26% |
Intangible Assets out of Total Assets |
0.62 | 0.40 | 0.51 | 0.52 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
3.69% | 4.27% | 4.42% | 3.70% | 4.70% | 6.43% | 17.74% | 23.51% | 9.69% | 17.44% |
Graham Net Nets |
(0.20) | (0.10) | (0.18) | (0.12) | 0.00 | 0.02 | 0.03 | 0.11 | 0.07 | (0.03) |
Graham Number |
4.89 | 15.03 | 5.53 | 6.43 | 9.48 | 4.89 | 0.00 | 0.00 | 3.71 | 2.15 |
Earnings Yield |
3.88% | 7.32% | 5.72% | 2.68% | 7.09% | 2.25% | (2.82%) | (3.79%) | 1.98% | (8.11%) |
Free Cash Flow Yield |
7.99% | 7.72% | 7.57% | 3.46% | 5.27% | 0.93% | (3.50%) | (2.58%) | 4.82% | (4.19%) |
Revenue per Share |
11.65 | 8.01 | 6.29 | 4.82 | 3.15 | 1.96 | 1.36 | 1.06 | 2.32 | 1.15 |
Operating CF per Share |
5.44 | 3.78 | 2.95 | 1.75 | 2.13 | 0.41 | (0.59) | (0.34) | 0.98 | (0.39) |
Capex per Share |
(0.06) | (0.08) | (0.12) | 0.15 | (0.01) | (0.01) | (0.03) | (0.03) | (0.01) | (0.02) |
Free Cash Flow per Share |
5.38 | 3.69 | 2.83 | 1.91 | 2.12 | 0.40 | (0.62) | (0.38) | 0.97 | (0.42) |
Cash per Share |
1.19 | 4.70 | 2.55 | 2.65 | 5.27 | 2.70 | 2.92 | 2.47 | 3.44 | 1.60 |
Shareholders Equity per Share |
0.41 | 2.87 | 0.64 | 1.24 | 1.40 | 1.11 | 0.64 | 1.73 | 1.53 | (0.25) |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
0.41 | 2.87 | 0.64 | 1.24 | 1.40 | 1.11 | 0.64 | 1.73 | 1.53 | (0.25) |
Free Cash Flow |
644.59 | 468.37 | 373.28 | 261.31 | 297.98 | 54.03 | (89.46) | (54.16) | 132.70 | (53.52) |
Working Capital |
648.12 | 946.24 | 633.93 | 608.22 | 809.14 | 133.38 | 457.80 | 278.49 | 379.04 | 201.95 |
Capital Expenditures |
(6.97) | (10.70) | (15.29) | 21.20 | (1.46) | (1.43) | (4.04) | (4.66) | (1.35) | (3.14) |
Net Current Asset Value |
(1,651.30) | (614.32) | (903.04) | (932.70) | 18.81 | 125.89 | 69.33 | 236.49 | 198.79 | (37.46) |
EV/EBIT |
22.98 | 12.70 | 18.15 | 32.47 | 20.99 | 43.26 | 0.00 | 0.00 | 30.73 | 0.00 |
Capex to Sales |
0.01 | 0.01 | 0.02 | (0.03) | 0.00 | 0.01 | 0.02 | 0.03 | 0.00 | 0.02 |
Price to Operating Income |
17.20 | 11.00 | 14.61 | 28.20 | 20.50 | 40.33 | 0.00 | 0.00 | 34.02 | 0.00 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
1.12 | 1.04 | 1.15 | 0.78 | 1.01 | 1.72 | 0.38 | 0.11 | 1.03 | 3.66 |
Cash ROIC |
27.61% | 19.00% | 19.45% | 12.82% | 16.42% | 5.90% | (9.77%) | (7.42%) | 15.08% | (13.75%) |
Accounts Receivable Turnover |
3.73 | 3.74 | 3.56 | 4.10 | 4.70 | 3.41 | 4.38 | 5.83 | 16.75 | 6.10 |
Accounts Payable Turnover |
14.69 | 14.45 | 13.04 | 14.49 | 46.94 | 10.37 | 8.66 | 1.69 | 5.41 | 8.22 |
Inventory Turnover |
1.44 | 1.18 | 1.69 | 1.81 | 1.42 | 0.96 | 1.75 | 0.73 | 3.15 | 2.75 |
Average Days of Payables |
33.34 | 23.47 | 22.42 | 46.36 | 6.91 | 16.23 | 51.56 | 146.89 | 93.12 | 39.33 |
Days of Inventory on Hand |
281.56 | 324.80 | 242.12 | 262.34 | 241.69 | 511.28 | 235.28 | 814.73 | 60.29 | 160.74 |
Average Receivables |
374.86 | 271.33 | 232.64 | 161.02 | 94.35 | 78.59 | 44.72 | 26.07 | 18.91 | 24.05 |
Average Payables |
15.57 | 11.03 | 14.75 | 9.62 | 1.73 | 4.18 | 5.26 | 6.01 | 5.76 | 4.04 |
Average Inventory |
159.17 | 134.73 | 113.86 | 77.02 | 57.33 | 45.05 | 25.99 | 13.89 | 9.88 | 12.06 |
Average Assets |
2,294.40 | 1,898.37 | 1,787.39 | 1,472.97 | 842.18 | 572.90 | 503.06 | 480.10 | 390.73 | 221.65 |
Average Common Equity |
206.32 | 223.81 | 126.80 | 183.38 | 174.00 | 121.41 | 170.33 | 228.63 | 87.94 | 5.26 |
Columns are period end dates